AT1's Principal Activity is the development and sale of medical devices.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+3.16%|
|vs ASX 200 (1yr)||-14.20%|
|ASX Rank||868 of 2,311|
|Sector Rank||73 of 197|
Atomo Diagnostics Limited (AT1) is a medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Ms Deborah Neff||Non-Executive Director||Sep 2021||
Ms Deborah Neff
Ms Neff has experience in building businesses and product commercialization in life sciences industry. Currently, she is advising several early-stage companies developing innovative technology to improve patient care. Most recently, she was the CEO of, Evanostics, LLC, a development stage company focused on systems for applications in point-of-care diagnostic testing in forensic and clinical toxicology. Prior to that, she was the Chief Operating Officer at Complete Genomics Inc., a life sciences company in whole genome and exome sequencing. Deborah continues as the principal of a privately held consulting company, DJN Consulting, LLC. that she formed in 2013. Prior to Complete Genomics, Deborah served as the Chief Operating Officer of Pathwork Diagnostics, Inc. and previously as CEO of Predicant Biosciences Inc. Deborah served as the global president of BD Biosciences, a major business segment of Becton Dickinson and Company until 2003. Her work experience at BD Biosciences over 15 years included various management positions including general manager, vice president and director of several business areas. Deborah's work in life sciences has included the areas of cancer diagnostics, immunocytometry and genomics, having establishing a certified clinical laboratory, guiding a molecular diagnostic test through the FDA clearance process, securing reimbursement pathways, and building commercial pipelines. Deborah served as a board member and executive management advisor for Galt Inc. and Vortex Biosciences Inc, and served on the board of BioRad, Inc. She is a former board member of Advanced Medical Optics, Inc. and ForteBio Corporation Inc., boards, which were acquired by Abbott Laboratories and Pall Corporation respectively. Deborah is an Executive Trustee of the UC Davis Foundation Board and Chairs the Global Campaign Leadership Committee. She also chairs the College of Biological Sciences Dean's Leadership Council at the University. Deborah also completed executive programs in marketing, finance, operations, and management at UCLA, Wharton, Stanford, and Harvard business schools.
|Ms Constance (Connie) Bernadette Carnabuci||Non-Executive Director||Feb 2020||
Ms Constance (Connie) Bernadette Carnabuci
Ms Carnabuci has over 30 years of experience advising intellectual property and technology businesses in Australia and across Asia on commercial, corporate and regulatory matters. Ms Carnabuci holds an executive role as the General Counsel of the Australian Broadcasting Corporation. She is a professional Non-Executive Director and currently serves on the Board and the Remuneration Committee of OFX. Ms Carnabuci is a former partner of Mallesons Stephen Jacques and Freshfields Bruckhaus Deringer. She is a member of the Business Advisory Council of the UNSW Business School. She serves as the Vice President of the Cranbrook School Parents Association. She was the Chair of the NFP, Kids Giving Back, from 2015 to 2018.
|Dr Curt Harold LaBelle||Non-Executive Director||Oct 2016||
Dr Curt Harold LaBelle
Dr LaBelle has been involved in the healthcare industry for 20 years, both operationally and as an investor. Dr LaBelle is President at the Global Health Investment Fund (GHIF). He also serves as a director on the boards of Alydia Health, Evenovia and Atticus Medical. Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He is a former chairman of Impulse Monitoring (acquired by Nuvasive), Exagen Inc. (NASDAQ:XGN) and a former director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen). Dr LaBelle is also the member of Risk committee.
|Mr John Perry Keith||Non-Executive Chairman,Non-Executive Director||Dec 2011||
Mr John Perry Keith
Non-Executive Chairman,Non-Executive Director
Mr Keith is a Managing Director of BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking. He has also served on the boards of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation. He is also the member of Risk committee.
|Mr John Michael Kelly||Founder,Chief Executive Officer,Managing Director||Apr 2010||
Mr John Michael Kelly
Founder,Chief Executive Officer,Managing Director
Mr Kelly was into developing and commercialising medical devices for more than 20 years to enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing 'Unifill'. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of Mirage Swift and Activa mask systems.
|Dr Paul Alexander Kasian||Non-Executive Director||N/A||
Dr Paul Alexander Kasian
Dr Kasian is an experienced executive director in both domestic and international companies in senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. Previously he served as a Non-Executive Director, then Chairman and CEO of Genetic Technologies Limited (appointed 12 December 2013 and resigned 23 September 2019). Dr Kasian is the Chair of the Risk Committee.
|Ms Gillian Maria Nairn||Company Secretary||N/A|
|Fabio Baglioni||Chief Commercial Officer||N/A|
|William Souter||Chief Financial Officer||N/A|
|Mark Smith||Chief Operating Officer||N/A|
AT1 directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|09/04/21||Curt LaBelle||Buy||+960,000||$0.156||$150,000||Exercise of options|
|09/04/21||Curt LaBelle||Exercise||960,000||$0.156||$150,000||Exercise of options|
|09/04/21||Curt LaBelle||Buy||+240,000||$0.156||$37,500||Exercise of options|
|09/04/21||Curt LaBelle||Exercise||240,000||$0.156||$37,500||Exercise of options|
The current holdings of AT1 directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Constance (Connie) Carnabuci||30/06/2020||N/A||75,000||N/A||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Global Health Investment Fund I LLC||25/09/2020||63,851,280||11.38|
|SG Hiscock and Company Limited||10/09/2021||20,909,532||5.12|
|Ellerston Capital Limited||15/09/2021||41,586,285||7.31|
|Walker Group Holdings Pty Limited||19/10/2020||37,660,718||6.70|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|15-09-21||Ellerston Capital Limited||7,211,285||6.13||7.31|
|10-09-21||SG Hiscock and Company Limited||20,909,532||--||5.12|
|29-06-21||Perennial Value Management Limited||7,334,006||6.35||7.56|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|09-08-21||Perennial Value Management Limited||42,962,957||7.56||--|
|19-10-20||Walker Group Holdings Pty Limited||9,000,000||8.32||6.70|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.